HQH
Financial ServicesAbrdn Healthcare Investors · Asset Management · $1B
What is Abrdn Healthcare Investors?
Abrdn Healthcare Investors (HQH) is a closed-end fund focused on global healthcare equities, with a particular emphasis on small-cap growth companies across biotechnology, medical devices, and pharmaceuticals. Managed by abrdn Inc., it has operated since the late 1980s.
HQH invests in publicly traded healthcare companies worldwide, concentrating on small-cap growth stocks in biotechnology, medical devices, and pharmaceuticals. The management team applies fundamental analysis, evaluating factors such as market position, management experience, technological expertise, and a company's ability to finance its own growth or attract outside capital. Performance is benchmarked against the NASDAQ Biotechnology Index, the S&P 500, and the S&P 1500 Healthcare Index.
The fund was formed in 1987 and is domiciled in Philadelphia, United States.
- Actively managed closed-end fund structure
- Global healthcare equity exposure
- Focus on small-cap biotechnology and pharma growth stocks
- Medical devices sector allocation
- Fundamental, research-driven portfolio construction
Is HQH a Good Stock to Buy?
UQS Score rates HQH as Good overall, reflecting a balanced but nuanced profile across its five pillars.
The fund's Growth pillar stands out as Strong, suggesting its underlying holdings are positioned in areas of above-average expansion potential within the healthcare sector. Valuation is rated Attractive, meaning the fund does not appear richly priced relative to its peers — a meaningful consideration for closed-end fund investors who watch discounts to net asset value.
The Moat and Risk pillars are both rated Weak, reflecting the inherent volatility of small-cap biotech investing and the limited structural advantages a fund vehicle can claim over its category.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does HQH pay dividends?
Yes — Abrdn Healthcare Investors pays a dividend.
HQH pays a regular dividend, which is common among closed-end funds that distribute income and realized gains to shareholders on a recurring basis. For a healthcare-focused fund investing primarily in growth-oriented small-caps, distributions are a key part of the total-return proposition. Investors should review the fund's distribution policy directly, as payouts can include return of capital components.
When does HQH report earnings?
Abrdn Healthcare Investors reports on a quarterly cadence, consistent with US-listed closed-end fund disclosure requirements.
As a closed-end fund, HQH's reported results reflect changes in net asset value, portfolio composition, and distribution coverage rather than traditional corporate earnings. The healthcare sector's inherent volatility — particularly in small-cap biotech — means quarterly results can shift meaningfully based on portfolio holdings.
For the most recent quarter's results and NAV updates, visit Abrdn Healthcare Investors' official investor relations page.
HQH Price History
+34.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Abrdn Healthcare Investors?
Based on Abrdn Healthcare Investors's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
HQH Long-term Outlook
HQH's Strong Growth pillar suggests the fund's portfolio is tilted toward healthcare companies with above-average expansion trajectories, particularly in biotechnology and medical devices. However, the Weak Risk pillar is a reminder that small-cap healthcare investing carries meaningful uncertainty — clinical trial outcomes, regulatory decisions, and sector sentiment can all drive sharp swings. The Attractive Valuation label adds a constructive dimension for patient investors willing to accept that volatility.
Growth drivers
- Structural tailwinds in biotechnology innovation and drug development pipelines
- Aging global demographics increasing demand for healthcare products and services
- Small-cap healthcare companies with high growth potential in the fund's core focus areas
Key risks
- High volatility inherent in small-cap biotech and pharmaceutical holdings
- Regulatory and clinical-trial risk affecting individual portfolio companies
- Closed-end fund discount widening during periods of sector stress
HQH vs Peers
HQH operates in a niche corner of the closed-end and specialty finance fund universe, where investors compare it against other income-oriented vehicles.
Horizon focuses on venture lending to technology and life sciences companies rather than equity ownership, offering a different risk-return profile.
Trinity Capital's notes represent a fixed-income instrument from a business development company, contrasting with HQH's equity-focused healthcare mandate.
This Canadian split-share fund targets dividend income across a broad basket of equities, rather than concentrating in healthcare growth stocks.
Frequently Asked Questions
What does Abrdn Healthcare Investors do?
Abrdn Healthcare Investors is a closed-end fund that invests in publicly traded healthcare companies around the world. It concentrates on small-cap growth stocks in biotechnology, medical devices, and pharmaceuticals, using fundamental research to build its portfolio.
Does HQH pay dividends?
Yes, HQH pays a regular dividend. As a closed-end fund, its distributions can include income, realized capital gains, and in some cases return of capital. Investors should review the fund's distribution history and policy on its official investor relations page.
When does HQH report earnings?
Abrdn Healthcare Investors reports on a quarterly cadence, typical for US-listed closed-end funds. For exact reporting dates and the most recent NAV and portfolio disclosures, check the fund's investor relations page directly.
Is HQH a good stock to buy?
UQS Score rates HQH as Good overall. Its Growth pillar is Strong and Valuation is Attractive, but the Moat and Risk pillars are both Weak — reflecting the volatility common in small-cap biotech funds. Whether it fits your portfolio depends on your risk tolerance and investment horizon.
Is HQH overvalued?
The UQS Valuation pillar for HQH is rated Attractive, suggesting the fund is not trading at a premium relative to peers. Closed-end funds can trade at discounts or premiums to net asset value, so monitoring that spread is important alongside any valuation assessment.
How does HQH compare to its competitors?
HQH is distinct from many peers in its pure focus on healthcare equity growth stocks, particularly small-cap biotech. Competitors like Horizon Technology Finance and Trinity Capital operate in lending or fixed-income structures, while HQH takes direct equity exposure to the healthcare sector.
What is HQH's market cap bracket?
HQH is classified as a small-cap fund. This reflects the total market value of the fund itself, separate from the market capitalizations of the individual companies it holds in its portfolio.
Who founded Abrdn Healthcare Investors?
The fund was formed in 1987 and is managed by abrdn Inc. Detailed founding history and management background are publicly available through the fund's official disclosures and abrdn's corporate history.
Is HQH a long-term quality investment?
From a long-term quality standpoint, HQH's Good UQS Score reflects genuine strengths in growth potential and valuation, tempered by Weak scores on Moat and Risk. Long-term investors should weigh the fund's concentration in volatile small-cap healthcare names against its growth-oriented mandate.
What is the main competitive advantage of Abrdn Healthcare Investors?
HQH's primary edge lies in its specialized focus — decades of experience investing in global healthcare equities, particularly small-cap biotech and pharma growth stocks. The fund's fundamental research process targets companies with strong management, technological expertise, and credible paths to financing growth.
What sector does HQH belong to?
HQH is classified under Financial Services as a closed-end fund, but its investment mandate is entirely focused on the healthcare sector — specifically biotechnology, medical devices, and pharmaceuticals across global public equity markets.
Is HQH a growth fund or an income fund?
HQH blends both characteristics. Its portfolio targets growth-oriented small-cap healthcare stocks, reflecting a Strong Growth pillar in the UQS framework. At the same time, it pays regular distributions, making it relevant for income-seeking investors as well.
Unlock Full HQH Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access full financial metrics and trend data
- ✓Compare HQH against sector peers side by side
- ✓See Growth and Valuation pillar details in depth
- ✓Get the complete analyst-grade quality view for Pro members
Pro Analysis
HQH — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | 58.5 | 77.3 | 12.0 | 81.3 | 36.4 | 96.7 | -0.3 |
| May 9, 2026 | 58.8 | 77.4 | 12.0 | 81.3 | 36.4 | 98.5 | +0.4 |
| Apr 25, 2026 | 58.4 | 77.4 | 12.0 | 81.3 | 36.4 | 95.6 | -0.2 |
| Apr 21, 2026 | 58.6 | 77.4 | 12.0 | 81.3 | 36.4 | 97.3 | 0.0 |
| Apr 18, 2026 | 58.6 | 77.4 | 12.0 | 81.3 | 36.4 | 97.0 | +1.0 |
| Apr 15, 2026 | 57.6 | 61.5 | 12.0 | 81.3 | 60.4 | 93.0 | -0.3 |
| Apr 14, 2026 | 57.9 | 61.5 | 12.0 | 81.3 | 60.4 | 94.9 | -0.3 |
| Apr 11, 2026 | 58.2 | 61.5 | 12.0 | 81.3 | 60.4 | 97.0 | -0.2 |
| Apr 10, 2026 | 58.4 | 61.5 | 12.0 | 81.3 | 60.4 | 97.9 | -0.1 |
| Apr 9, 2026 | 58.5 | 61.5 | 12.0 | 81.3 | 60.4 | 98.9 | -0.2 |
HQH — Pillar Breakdown
Quality
— 77.4/100 (25%)Abrdn Healthcare Investors demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 81.3/100 (20%)Abrdn Healthcare Investors is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 36.4/100 (15%)Abrdn Healthcare Investors has some risk factors including moderate leverage or solvency concerns.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 97.7/100 (15%)Abrdn Healthcare Investors appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
Enterprise value multiple relative to sector median.
Moat
— 12/100 (25%)Abrdn Healthcare Investors operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HQH.
Score Composition
Financial Data
More Stock Analysis
How is the HQH UQS Score Calculated?
The UQS (Unified Quality Score) for Abrdn Healthcare Investors is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Abrdn Healthcare Investors's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Abrdn Healthcare Investors is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.